Epstein Secrets

ge in new cases that threatens to spiral out of control." After Initial Success, Israel Sees Spike In Coronavirus Cases. The Washington Post (7/7, Hendrix, 14.2M) reports that Israel's "deft handling of its coronavirus outbreak this spring won praise at home and abroad, but the virus has returned, wit

shown to be effective in clinical trials." CNN (7/7, Cohen, Bonifield, 83.16M) reports on its website that Novavax CEO/President Stanley Erck "said Novavax's vaccine could be on the market by the first quarter of next year." The Hill (7/7, Budryk, 2.98M) reports that "the award will also cover a large-

rnment To Pay $1.6B For Rush Vaccine Development. The CBS Evening NewsVi (7/7, story 3, 1:40, O'Donnell, 4.24M) reported, "Maryland biotech company Novavax is in the hunt for a coronavirus vaccine, and getting a major dose of funding from the government's Operation Warp Speed program." The New York lime

minister-visits-saudi-arabia-meets- with-crown-prince-and-pompeo-say-local-media/2020/11/23/63f3cab4-2d5f-lleb-9dd6- 2d0179981719_story.html> (11/23, Hendrix, Rubin, Mekhennet, I4.2M) calls it "a watershed visit in the historically hostile relations between the two countries." It also quotes an unnamed "i

ted by more than $10 billion in U.S taxpayer dollars. The government is also supporting an experimental vaccine from Sanofi/GSK and one from startup Novavax, which are expected to begin large trials in the U.S. in the coming weeks. Merck, which has received far less funding, is a few months further behi

lized ties between Israel and the broader Arab world and reflected the shared concern of all three nations about Iran." The Washington Post (11/23, Hendrix, Rubin, Mekhennet, 14.2M) calls it "a watershed visit in the historically hostile relations between the two countries." It also quotes an unnamed "

ed by more than $10 billion in U.S taxpayer dollars. The government is also supporting an experimental vaccine from Sanofi/GSK and one from startup Novavax, which are expected to begin large trials in the U.S. in the coming weeks. Merck, which has received far less funding, is a few months further behin